Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an
Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhead

Media Release 

  *Antibody-drug conjugate (ADC) to be developed for cancer
  *Combines strength of HuMax^(R)-TAC with next generation PBD-based warhead
  *50:50 partnership

COPENHAGEN, Denmark and LAUSANNE, Switzerland, June 17, 2013 (GLOBE NEWSWIRE)
-- Genmab A/S (Copenhagen:GEN) and ADC Therapeutics Sarl announced today an
agreement to develop a new antibody-drug conjugate (ADC) product combining
Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker
technology. The Companies have been conducting in vitro and in vivo studies
since 2012 to investigate different warhead and linker combinations with
HuMax-TAC, and now have the product ready for pre-IND preclinical
development. The product will be developed for multiple cancer indications.

Genmab and ADC Therapeutics will each initially have an equal share in the
product. In the first instance, ADC Therapeutics will lead and fund
preclinical development. Prior to the submission of an application to conduct
clinical studies in patients (IND filing), Genmab may elect to retain equal
ownership of the product.Genmab will not incur any development costs prior to
the IND filing decision and Genmab will maintain a minimum 25% ownership stake
in the product as it moves into clinical development. No other financial terms
were disclosed.

"We believe our unique HuMax-TAC antibody has optimal characteristics for
creation of an ultra-potent antibody-drug conjugate when used in combination
with ADC Therapeutics' novel PBD-based warhead and linker technology, which
employs an emerging class of highly potent anticancer agents.This agreement
is another example of a win-win partnership combining Genmab's
state-of-the-art antibody development expertise with the latest advance in
antibody-payload technology," said Jan van de Winkel, Ph.D., Chief Executive
Officer of Genmab.

Dr. Peter B. Corr, Chairman of ADC Therapeutics said: "We are very excited to
be developing an ADC with our new partner Genmab and incorporating our next
generation PBD-based toxins into this product.Our warhead payload technology
enjoys exquisite potency, optimised conjugation and pharmaceutical properties
that maintain activity in highly resistant cancers.Our pre-clinical data for
this product indicate the potential for curative efficacy in highly resistant
populations at low ADC doses of this product in several oncology indications,
an area with critical unmet needs".

This agreement does not affect Genmab's 2013 financial guidance.

About HuMax-TAC

HuMax-TAC is a high-affinity fully human antibody targeting CD25, a
therapeutic target with strong clinical validation. CD25 is expressed on a
variety of hematological tumors and shows limited expression on normal
tissues, which makes it a very attractive target for antibody-payload
approaches. With HuMax-TAC-ADC, we aim to develop a first-in-class
antibody-drug conjugate for the potential treatment of CD25-expressing
lymphomas and leukemias.

About PBD Warheads & Linkers

ADCs developed using ADC Therapeutics' technology combine monoclonal
antibodies specific to particular tumor targets with highly potent
pyrrolobenzodiazepine (PBD) based warheads developed by ADC Therapeutic's
partner Spirogen Limited. These PBD warheads are joined to antibodies by
linkers that release the PBD warhead in the targeted cancer cells. This
technology has attracted the attention of other biotechnology companies such
as Genentech and Seattle Genetics.

About ADC Therapeutics

ADC Therapeutics Sarl (ADCT) is a Swiss-based oncology drug development
company that specializes in the development of proprietary Antibody Drug
Conjugates (ADCs) targeting major cancers such as breast, lung, prostate,
renal and blood. The Company's ADCs are highly targeted drug constructs which
combine monoclonal antibodies specific to particular types of tumor cells with
a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As
its PBD-based chemistries do not distort the structure of the DNA it gives the
prospect of highly potent, target-selective cancer therapies with fewer side
effects and the potential to pre-empt resistance issues faced by other
anti-cancer products on the market. The company was formed in 2012 with a $50m
commitment from private equity firm Auven Therapeutics (previously known as
Celtic Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd,
also an Auven Therapeutics' portfolio company, for the supply of warhead
chemistries and R&D services. It operates a virtual business model based in
Lausanne, Switzerland.

For further information please

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra^(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit

Contact Genmab:

Rachel Curtis Gravesen, Senior Vice President, Investor Relations &

T: +45 33 44 77 20; M: +45 25 12 62 60; E:

Contact ADC Therapeutics:

Sue Charles/Stefanie Bacher/Gemma Howe, College Hill Life Sciences (PR Agency
for ADC Therapeutics)

T: +44 (0) 20 7457 202; E:

This Media Release contains forward looking statements. The words "believe",
"expect", "anticipate", "intend" and "plan" and similar expressions identify
forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on . Genmab does not
undertake any obligation to update or revise forward looking statements in
this Media Release nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^(R); the
Y-shaped Genmab logo^(R); HuMax^(R); HuMax-CD20^(R); DuoBody^(R), HexaBody^TM
and UniBody^(R). Arzerra^(R) is a trademark of GlaxoSmithKline.

Media Release no. 04

CVR no. 2102 3884

Genmab A/S

Bredgade 34E

1260 Copenhagen K

Press spacebar to pause and continue. Press esc to stop.